Literature DB >> 1609297

Progress in chemotherapy for metastatic breast cancer.

G W Sledge1, K H Antman.   

Abstract

Entities:  

Mesh：

Year:  1992        PMID： 1609297

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  8 in total

Review 1.  Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.

Authors:  L R Wiseman; C M Spencer
Journal:  Drugs Aging       Date:  1998-04       Impact factor: 3.923

Review 2.  Clodronate: a review of its use in breast cancer.

Authors:  M Hurst; S Noble
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

Review 3.  Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.

Authors:  H M Lamb; L R Wiseman
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

Review 4.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

5.  Mitoxantrone plus vinorelbine with granulocyte-colony stimulating factor (G-CSF) support in advanced breast cancer patients. A dose and schedule finding study.

Authors:  G Frasci; G Comella; P Comella; F Salzano; L Cremone; N Della Volpe; A Imbriani; G Persico
Journal:  Breast Cancer Res Treat       Date:  1995-08       Impact factor: 4.872

6.  High-dose chemotherapy with autologous stem cell rescue in breast cancer.

Authors:  R O Dillman; N M Barth; S K Nayak; C DeLeon; A O'Connor; L Morrelli
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 7.  Management of metastatic breast cancer.

Authors:  K Wong; I C Henderson
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

Review 8.  Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer.

Authors:  B Fulton; C M Spencer
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.